Drug Treatment | No. (%) |
---|---|
Gold duration (mo) at last visit in 2009, n = 71* | |
≥ 5 | 25 (35) |
6 to 10 | 14 (20) |
11 to 20 | 22 (31) |
≥ 20 | 10 (14) |
Concomitant DMARD, n = 71* | |
None | 12 (17) |
1 DMARD | 36 (51) |
2 DMARD | 18 (25) |
3 DMARD | 2 (3) |
1 biologic | 1 (1) |
≥ 1 DMARD + biologic | 2 (2) |
Concomitant gold/DMARD combinations, n = 71* | |
Gold alone | 12 (17) |
Gold + MTX | 11 (15) |
Gold + HCQ | 20 (28) |
Gold + SSZ | 3 (4) |
Gold + CyA | 2 (3) |
Gold + anti-TNF | 1 (1) |
Gold + MTX + HCQ | 12 (17) |
Gold + MTX + SSZ | 2 (3) |
Gold + MTX + LEF | 1 (1) |
Gold + MTX + anti-TNF | 2 (3) |
Gold + HCQ + SSZ | 3 (4) |
Gold + MTX + chloroquine + LEF | 1 (1) |
Gold + MTX + HCQ + SSZ | 1 (1) |
↵* Counts and percentages based on available data. Ten patients never started gold and thus disease duration and age at time of admission to clinic were not applicable. MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; CyA: cyclosporin A; anti-TNF: anti-tumor necrosis factor (includes etanercept, adalimumab, and/or infliximab); LEF: leflunomide.